PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.

Autor:	Alderuccio JP; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Reis IM; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Hamadani M; Medical College of Wisconsin, Milwaukee, Wisconsin., Nachiappan M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Leslom S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Kahl BS; Washington University, St. Louis, Missouri., Ai WZ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California., Radford J; NIHR Clinical Research Facility, University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom., Solh M; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia., Ardeshna KM; University College London Hospitals NHS Foundation Trust, London, United Kingdom., Hess BT; Medical University of South Carolina, Charleston, South Carolina., Lunning MA; University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center, Omaha, Nebraska., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli'; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Stathis A; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland., Carlo-Stella C; Department of Biomedical Sciences, Humanitas University, Milano, Italy.; Department of Oncology and Hematology, Humanitas Research Hospital-IRCCS, Milano, Italy., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Caimi PF; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Han S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Yang F; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Kuker RA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Moskowitz CH; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jan 05; Vol. 30 (1), pp. 139-149.
DOI:	10.1158/1078-0432.CCR-23-1561
Abstrakt:	Purpose: Significant progress has occurred in developing quantitative PET/CT biomarkers in diffuse large B-cell lymphoma (DLBCL). Total metabolic tumor volume (MTV) is the most extensively studied, enabling assessment of FDG-avid tumor burden associated with outcomes. However, prior studies evaluated the outcome of cytotoxic chemotherapy or chimeric antigen receptor T-cell therapy without data on recently approved FDA agents. Therefore, we aimed to assess the prognosis of PET/CT biomarkers in patients treated with loncastuximab tesirine. Experimental Design: We centrally reviewed screening PET/CT scans of patients with relapsed/refractory DLBCL enrolled in the LOTIS-2 (NCT03589469) study. MTV was obtained by computing individual volumes using the SUV ≥4.0 threshold. Other PET/CT metrics, clinical factors, and the International Metabolic Prognostic Index (IMPI) were evaluated. Logistic regression was used to assess the association between biomarkers and treatment response. Cox regression was used to determine the effect of biomarkers on time-to-event outcomes. We estimated biomarker prediction as continuous and binary variables defined by cutoff points. Results: Across 138 patients included in this study, MTV with a cutoff point of 96 mL was the biomarker associated with the highest predictive performance in univariable and multivariable models to predict failure to achieve complete metabolic response (OR, 5.42; P = 0.002), progression-free survival (HR, 2.68; P = 0.002), and overall survival (HR, 3.09; P < 0.0001). IMPI demonstrated an appropriate performance, however, not better than MTV alone. Conclusions: Pretreatment MTV demonstrated robust risk stratification, with those patients demonstrating high MTV achieving lower responses and survival to loncastuximab tesirine in relapsed/refractory DLBCL. (©2023 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu